Figure 3.

Visceral fat and Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) over time by fibrosis progression status in human immunodeficiency virus–associated NAFLD. A, Among placebo-treated participants, baseline NAS did not distinguish between hepatic fibrosis progressors and nonprogressors. However, over the study period, fibrosis progressors exhibited a rise in NAS, whereas nonprogressors showed a mild decline in this parameter. B, At baseline, visceral fat content differentiated hepatic fibrosis progressors vs nonprogressors. This difference in visceral fat between groups was maintained throughout the study period. Data points and error bars indicate mean ± standard error of the mean.